CDMO：

 Sintaho focuses on providing high-quality small molecule APIs and CDMO services to global pharmaceutical enterprises, with the product series represented by cytotoxic and high activity small molecule APIs. Sintaho currently has R&D lab areas of over 1000㎡, and production areas of over 19700㎡. The company has built cytotoxic OEB5 workshops, a sewage treatment system managed by a comprehensive EHS management system and an advantageous quality management system surpassing cGMP and ICH requirements, to ensure efficient CDMO services for global pharmaceutical enterprises.

  Sintaho is committed to "Produce High Quality Pharmaceuticals to Improve Human Health" with China-based and global view, aimed to be a world-class supplier of oncology APIs. We provide CDMO and the corresponding RA one-stop services to global customers for advanced excipients and APIs.